Show notes
Send us Fan MailHow will Most Favored Nation (MFN) pricing reshape global pharmaceutical strategy? What do emerging Centers for Medicare & Medicaid Service (CMS) models such as GENEROUS, GLOBE, and GUARD mean for launch planning, pricing corridors, and payer expectations worldwide? How should global market access teams prepare for a more transparent and tightly connected pricing environment?MFN reform is already influencing how companies plan, price, and launch medicines around the world. While CMS proposals sit at the center of the debate, the implications extend far beyond the US. The increased transparency required in models under consideration has the potential to accelerate global price convergence, affect international reference dynamics, and place new pressures on evidence generation, launch sequencing, and global pricing corridors.This episode was first broadcast as a live webinar on Wednesday 15th April 2026. It is designed to help global and US teams understand and anticipate the worldwide strategic implications of MFN policy. The session brought together four experts offering global and US perspectives on MFN:Steve O’Malley (President, Petauri Advisors): Moderator and contributor on US access and strategic implicationsCatherine Beecher (Director – Global Pricing and Market Access, Petauri Evidence): Bringing insight into global evidence requirements, lifecycle planning, and cross‑market pricing pressuresClare Foy (Director – Global Pricing and Market Access, Petauri Evidence): Bringing expertise in global pricing strategy and launch planning across international marketsMichael Garner (Vice President, Artia Solutions – Powered by Petauri): Bringing US Medicaid expertise with a focus on CMS MFN proposals and their operational and strategic implicationsLearn more at: https://petauri.com/insights/global-market-access-strategy-for-mfn/In this webinar, we explored:The most recent CMS MFN policy developments and how models such as GENEROUS, GLOBE, and GUARD may evolveThe possible effects of the recent announcement of new tariffs on pharmaceutical manufacturersHow greater price transparency could affect international pricing corridors and global revenue forecastsImpacts on launched products, peri-launch assets, and early pipeline programs from both a global and US policy standpointStrategic options for optimizing ex-US price potential, including evidence generation, innovative agreements, conditional reimbursement, and launch sequencingHow global market access teams can build pricing and access strategies that remain resilient as MFN models evolveWider policy developments to monitor outside the US, including proposed changes to the exclusivity period in the EU, and the growing influence of the Joint Clinical AssessmentLearn more about our pricing and market access strategy services.Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence